Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Non-cash Items (2016 - 2025)

Seres Therapeutics' Non-cash Items history spans 11 years, with the latest figure at $499771.0 for Q3 2025.

  • For Q3 2025, Non-cash Items rose 103.99% year-over-year to $499771.0; the TTM value through Sep 2025 reached $499771.0, up 103.99%, while the annual FY2024 figure was $87000.0, N/A changed from the prior year.
  • Non-cash Items for Q3 2025 was $499771.0 at Seres Therapeutics, up from $87000.0 in the prior quarter.
  • Across five years, Non-cash Items topped out at $19.9 billion in Q1 2022 and bottomed at $87000.0 in Q4 2024.
  • The 5-year median for Non-cash Items is $10.8 million (2022), against an average of $2.7 billion.
  • The largest annual shift saw Non-cash Items surged 499438.5% in 2022 before it tumbled 99.94% in 2023.
  • A 5-year view of Non-cash Items shows it stood at $28.0 million in 2021, then plummeted by 58.55% to $11.6 million in 2022, then fell by 13.85% to $10.0 million in 2023, then plummeted by 99.13% to $87000.0 in 2024, then surged by 474.45% to $499771.0 in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Non-cash Items are $499771.0 (Q3 2025), $87000.0 (Q4 2024), and $245000.0 (Q3 2024).